Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS Press Releases

  • DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C
  • More than EUR 56 million raised to fund initiative to fight antibiotic resistance
  • U.S. FDA approves Chemo Group’s benznidazole to treat children with Chagas disease
  • DNDi welcomes Dr Marie-Paule Kieny as new Chair of the Board of Directors with Prof. Marcel Tanner stepping down after ten successful years
  • Antibiotic-resistant gonorrhoea on the rise; need for new drugs

RSS In the Media

  • The Huffington Post: “A deadly disease threatens to regain ground deep in the African jungle”
  • NPR: “Drug for ‘neglected’ Chagas disease gains FDA approval amid price worries”
  • Slate: “A new strategy to undermine big pharma’s price gouging actually worked”
  • Huffington Post: “In rural Kenya, escaping a deadly disease sometimes takes a little luck”
  • ISNTD Blog: “Infectious thoughts interviews”

RSS Scientific Articles

  • Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
  • Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform
  • Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial
  • Safety and efficacy of short course combination regimens with AmBisome®, miltefosine, paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
  • IFN-g, IL-2, IP-10, and MIG as biomarkers of exposure to leishmania spp., and of cure in human visceral leishmaniasis

RSS News

  • GARDP at one: R&D programmes getting underway
  • GHIT Fund reinforces its support to DNDi leishmaniasis and Chagas disease projects
  • R&D Status February 2017: DNDi Sleeping sickness programme
  • R&D Status February 2017: DNDi Leishmaniasis programme
  • R&D Status February 2017: DNDi Chagas disease programme

RSS Events

  • Geneva Health Forum
  • ASTMH 2017
  • AASLD The Liver Meeting®
  • ECTMIH 2017
  • International Workshop on Onchocerciasis-associated Epilepsy (OAE)

RSS Scientific Articles

  • Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
  • Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform
  • Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial
  • Safety and efficacy of short course combination regimens with AmBisome®, miltefosine, paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

 

Subscribe

Sign up for the E-news newsletter

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

  • TERMS OF USE
  • PRIVACY POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License